DEC 19, 2017 03:26 PM PST

The Flu!! New Targeting Strategies

Every year, around this time, we all fear the flu. Everyone runs to get their vaccine and hopes for the best. Yet, inevitably, there is always that co-worker that comes down with the flu anyway, and then so does a number of other people, and then occasionally so do you. Okay, so maybe not everyone gets their vaccination, but even if you do you still sometimes might fall sick. Why is this? Well every year the season flu strain is different. More scientifically, influenza A H3N2 and H1N1 subtypes and influenza B Yamagata and Victoria lineages remain constantly evolving, dynamic threats to our health each year, on a global scale. This is not due to lack of vaccines and antiviral drugs, just lack of their ability to target that they are meant to. These strains of virus have evolved into genetically distinct lineages, and these lineages have continued to co-circulate for decades.

According to a recent article published in Science Translational Medicine, a group of researchers lead by Ninshao Xia from China sought to address the current limitations of influenza vaccines and antivirals. They summed up the limitations of current strategies simply: “Current vaccines struggle to induce sufficient levels of cross-reactive neutralizing antibodies, and vaccine strains frequently become mismatched from continuously evolving influenza variants. In addition, the effectiveness of existing antiviral drugs for the treatment of influenza infection is limited because of short treatment windows and emerging antiviral drug resistance. Thus, there is an unmet medical need to develop more effective universal prophylactic and therapeutic approaches against influenza infection.” This is exactly what this group set out to address.

Recently, what is known as ‘broadly neutralizing antibodies’ have emerged as a new strategy to address the issue of the elusive influenza. These are essentially antibodies that target antigens that are ever present, and are weak points for the virus. So while the virus may be ever changing, it maintains these antigens as part of itself regardless of how it might evolve, and exploiting these antigens therapeutically has the ability to cripple the disease. In the research from Dr. Xia’s group, they report the development of a chimeric monoclonal antibody which they call C12G66, that has the ability to cross neutralize viral strains spanning 76 years of influenza B by targeting hemagglutinin (HA). When tested in mice and ferrets, C12G6 was able to confer strong cross protection of these animals against various influenza B strains, and to a greater extent than any other vaccines tested. Further investigation revealed that this protection was due to C12G6 inhibiting the virus through multiple mechanisms. The others state that C12G6 could “prevent viral entry, egress, and HA-mediated membrane fusion and could trigger antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity responses.” In other words, it worked and it worked in multiple ways. To put it simply, C12G6 holds promise for the development of much more effective flu vaccine design and may lay the foundation for what could eventually be a “truly universal” flu vaccine.

Sources: Science Translational Medicine, Wikipedia, Pixabay, TedEd, Youtube

 

About the Author
You May Also Like
OCT 16, 2018
Drug Discovery
OCT 16, 2018
Anti-Venomous Plant Compound
According to a study published in PLOS Neglected Tropical Diseases, researchers at the Institute Butantan, São Paulo, Brazil, have discovered a flav...
NOV 05, 2018
Microbiology
NOV 05, 2018
Potential Antidote to Botulism is Found
A microbe called Clostridium botulinum and sometimes two other strains of Clostridium bacteria can make a toxic chemical called botulism....
NOV 12, 2018
Cancer
NOV 12, 2018
Targeted radiation therapy may provide new hope to children with difficult-to-treat liver cancer
Primary malignant liver tumors are rare in children with an occurrence rate of 1-2% of all childhood cancers. Radical surgical resection of the liver which means the removal of part of the li...
JAN 01, 2019
Drug Discovery
JAN 01, 2019
Restoring The Fountain of Youth
According to a study published in Nature Communications, a drug treatment that aided the immune system in eradicating old cells in aging mice assisted in t...
FEB 01, 2019
Cardiology
FEB 01, 2019
Parents Prefer Opioids For Their Children Despite Risks
Opioid abuse has become an epidemic in the United States. It is estimated that 72,000 deaths were the result of opioid abuse in 2017. The hardest hit state...
FEB 20, 2019
Drug Discovery
FEB 20, 2019
Possible New Drug To Combat African Sleeping Sickness
Scientists have teamed up to combat African sleeping sickness, which is caused by trypanosomes, unicellular protozoans transmitted by the bite of an infect...
Loading Comments...